Jade Biosciences (NASDAQ:JBIO – Get Free Report) had its price target cut by investment analysts at Guggenheim from $47.00 to $41.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim‘s price target indicates a potential upside of 154.03% from the stock’s previous close.
Other equities research analysts have also issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Jade Biosciences in a research report on Friday, September 11th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of Jade Biosciences in a report on Thursday, October 1st. Wedbush reissued an “outperform” rating and issued a $47.00 price objective on shares of Jade Biosciences in a research note on Thursday, October 1st. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 price objective on shares of Jade Biosciences in a research note on Tuesday, August 11th. Finally, Wall Street Zen upgraded Jade Biosciences from a “strong sell” rating to a “sell” rating in a report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.
Check Out Our Latest Stock Analysis on Jade Biosciences
Jade Biosciences Stock Performance
JBIO stock opened at $16.14 on Monday. The stock has a market capitalization of $1.03 billion, a P/E ratio of -8.68 and a beta of 1.81. The firm has a 50-day moving average price of $15.32 and a 200-day moving average price of $18.14. Jade Biosciences has a 12 month low of $9.60 and a 12 month high of $28.00.
Jade Biosciences (NASDAQ:JBIO – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.31. As a group, equities analysts predict that Jade Biosciences will post -2.89 EPS for the current fiscal year.
Institutional Trading of Jade Biosciences
Institutional investors and hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC purchased a new stake in shares of Jade Biosciences during the 1st quarter valued at approximately $43,557,000. Pictet Asset Management Holding SA grew its stake in Jade Biosciences by 64.4% in the 3rd quarter. Pictet Asset Management Holding SA now owns 1,205,972 shares of the company’s stock valued at $16,944,000 after buying an additional 472,204 shares in the last quarter. Jump Financial LLC raised its holdings in Jade Biosciences by 75.3% during the 3rd quarter. Jump Financial LLC now owns 302,812 shares of the company’s stock valued at $4,255,000 after acquiring an additional 130,065 shares during the period. Russell Investments Group Ltd. raised its holdings in Jade Biosciences by 10.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 179,432 shares of the company’s stock valued at $2,521,000 after acquiring an additional 16,348 shares during the period. Finally, Stempoint Capital LP purchased a new stake in shares of Jade Biosciences during the first quarter worth $2,164,000.
About Jade Biosciences
Jade Biosciences is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease. The company’s lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys. Jade’s pipeline is focused on potential therapies for autoimmune conditions.
Further Reading
- Five stocks we like better than Jade Biosciences
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for Jade Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
